Header Logo

Connection

Tom Boyles to Treatment Outcome

This is a "connection" page, showing publications Tom Boyles has written about Treatment Outcome.
Connection Strength

0,657
  1. Why do clinical trials of Xpert® MTB/RIF fail to show an effect on patient relevant outcomes? Int J Tuberc Lung Dis. 2017 03 01; 21(3):249-250.
    View in: PubMed
    Score: 0,454
  2. Factors influencing retention in care after starting antiretroviral therapy in a rural South African programme. PLoS One. 2011 May 03; 6(5):e19201.
    View in: PubMed
    Score: 0,076
  3. Fostamatinib for Hospitalized Adults With COVID-19 and Hypoxemia: A Randomized Clinical Trial. JAMA Netw Open. 2024 Dec 02; 7(12):e2448215.
    View in: PubMed
    Score: 0,049
  4. Treating drug-resistant tuberculosis in an era of shorter regimens: Insights from rural South Africa. S Afr Med J. 2023 Nov 06; 113(11):47-56.
    View in: PubMed
    Score: 0,045
  5. Low-dose ritonavir-boosted darunavir once daily versus ritonavir-boosted lopinavir for participants with less than 50 HIV RNA copies per mL (WRHI 052): a randomised, open-label, phase 3, non-inferiority trial. Lancet HIV. 2019 07; 6(7):e428-e437.
    View in: PubMed
    Score: 0,033
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.